Peripheral T-Cell Lymphoma

The FDA placed a partial clinical hold on two trials evaluating lacutamab for T-cell lymphomas after a patient died of hemophagocytic lymphohistiocytosis, according to the agent’s manufacturer.

The FDA granted fast track designation to MT-101, an investigational chimeric antigen receptor monocyte, for the treatment of relapsed or refractory peripheral T-cell lymphoma.

Bristol Myers Squibb withdrew the indication for romidepsin as treatment for relapsed or refractory peripheral T-cell lymphoma.

The FDA cleared an investigational new drug application for LB1901, a chimeric antigen receptor T-cell therapy in development for treatment of adults with relapsed or refractory T-cell lymphoma, according to the agent’s manufacturer.

Stefan K. Barta, MD, MS, MRCP, director of the T-Cell Lymphoma Program at Penn Medicine, discussed some promising treatments for T-cell lymphoma presented at the ASH Annual Meeting and Exposition.

The addition of romidepsin to CHOP did not improve PFS in patients with peripheral T-cell lymphoma, according to an analysis presented at ASH Annual Meeting and Exposition.

Geptanolimab, an anti-PD-1 antibody, appeared effective and safe for patients with relapsed or refractory peripheral T-cell lymphoma, according to results of a phase 2 multicenter trial presented at the virtual American Association for Cancer Research Annual Meeting.

The FDA granted fast track designation to tipifarnib for treatment of adults with one of several types of T-cell lymphoma, according to the agent’s manufacturer.

In 2016, the FDA approved the first immunotherapy for lymphoma. Since then, the field has exploded and now, just 4 years later, there are nine FDA-approved immunotherapy options for lymphoma, according to the Cancer Research Institute.